FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809898434> ?p ?o ?g. }

• W2809898434 endingPage "1783" @default.
• W2809898434 startingPage "1776" @default.
• W2809898434 abstract "Purpose To identify baseline factors associated with change in visual acuity or development of vision-impairing central-involved diabetic macular edema (DME) over 2 years when treating proliferative diabetic retinopathy (PDR) with ranibizumab or panretinal photocoagulation (PRP). Design Post hoc analyses of randomized, multicenter clinical trial data. Participants Eyes completing the 2-year visit (n = 328) or without vision-impairing central-involved DME at baseline (n = 302) in Diabetic Retinopathy Clinical Research Network Protocol S. Methods Intravitreous ranibizumab (0.5 mg/0.05 ml) or PRP. Main Outcome Measures Change in visual acuity (area under the curve) and development of vision-impairing (20/32 or worse) central-involved DME over 2 years. Results After multivariable model selection with adjustment for baseline visual acuity and central subfield thickness, no factors were identified as associated with change in visual acuity or development of vision-impairing central-involved DME within the ranibizumab group. In the PRP group, worse change in visual acuity was more likely with higher hemoglobin A1c level (–0.6 letters per 1% increase; 95% confidence interval [CI], –1.2 to –0.1 letters; continuous P = 0.03), more severe diabetic retinopathy (difference between high-risk PDR or worse vs. moderate PDR or better, –2.8 letters [95% CI, –5.5 to –0.2 letters]; continuous P = 0.003), and higher mean arterial pressure (difference between ≥100 mmHg vs. <100 mmHg, –2.0 letters [95% CI, –4.6 to 0.5 letters]; continuous P = 0.009). Development of vision-impairing central-involved DME was more likely with higher hemoglobin A1c level (hazard ratio [HR] per 1% increase, 1.31 [95% CI, 1.13–1.52]; continuous P < 0.001), more severe diabetic retinopathy (HR for high-risk PDR or worse vs. moderate PDR or better, 1.46 [95% CI, 0.73–2.92]; continuous P = 0.03), and the presence of cystoid abnormalities within 500 μm of the macula center (HR, 2.90 [95% CI, 1.35–6.24]; P = 0.006). Conclusions For eyes managed with PRP, higher hemoglobin A1c level and more severe diabetic retinopathy were associated with less vision improvement and an increased risk of vision-impairing central-involved DME developing. When managing PDR with ranibizumab, eyes gained vision, on average, with no baseline characteristics identified as associated with visual acuity or central-involved DME outcomes. To identify baseline factors associated with change in visual acuity or development of vision-impairing central-involved diabetic macular edema (DME) over 2 years when treating proliferative diabetic retinopathy (PDR) with ranibizumab or panretinal photocoagulation (PRP). Post hoc analyses of randomized, multicenter clinical trial data. Eyes completing the 2-year visit (n = 328) or without vision-impairing central-involved DME at baseline (n = 302) in Diabetic Retinopathy Clinical Research Network Protocol S. Intravitreous ranibizumab (0.5 mg/0.05 ml) or PRP. Change in visual acuity (area under the curve) and development of vision-impairing (20/32 or worse) central-involved DME over 2 years. After multivariable model selection with adjustment for baseline visual acuity and central subfield thickness, no factors were identified as associated with change in visual acuity or development of vision-impairing central-involved DME within the ranibizumab group. In the PRP group, worse change in visual acuity was more likely with higher hemoglobin A1c level (–0.6 letters per 1% increase; 95% confidence interval [CI], –1.2 to –0.1 letters; continuous P = 0.03), more severe diabetic retinopathy (difference between high-risk PDR or worse vs. moderate PDR or better, –2.8 letters [95% CI, –5.5 to –0.2 letters]; continuous P = 0.003), and higher mean arterial pressure (difference between ≥100 mmHg vs. <100 mmHg, –2.0 letters [95% CI, –4.6 to 0.5 letters]; continuous P = 0.009). Development of vision-impairing central-involved DME was more likely with higher hemoglobin A1c level (hazard ratio [HR] per 1% increase, 1.31 [95% CI, 1.13–1.52]; continuous P < 0.001), more severe diabetic retinopathy (HR for high-risk PDR or worse vs. moderate PDR or better, 1.46 [95% CI, 0.73–2.92]; continuous P = 0.03), and the presence of cystoid abnormalities within 500 μm of the macula center (HR, 2.90 [95% CI, 1.35–6.24]; P = 0.006). For eyes managed with PRP, higher hemoglobin A1c level and more severe diabetic retinopathy were associated with less vision improvement and an increased risk of vision-impairing central-involved DME developing. When managing PDR with ranibizumab, eyes gained vision, on average, with no baseline characteristics identified as associated with visual acuity or central-involved DME outcomes." @default.
• W2809898434 created "2018-07-10" @default.
• W2809898434 creator A5015264417 @default.
• W2809898434 creator A5021501498 @default.
• W2809898434 creator A5023376839 @default.
• W2809898434 creator A5053593038 @default.
• W2809898434 creator A5057741978 @default.
• W2809898434 creator A5058951987 @default.
• W2809898434 creator A5059376308 @default.
• W2809898434 creator A5061503632 @default.
• W2809898434 date "2018-11-01" @default.
• W2809898434 modified "2023-10-13" @default.
• W2809898434 title "Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy" @default.
• W2809898434 cites W1973545783 @default.
• W2809898434 cites W2006529377 @default.
• W2809898434 cites W2122595579 @default.
• W2809898434 cites W2171946822 @default.
• W2809898434 cites W2178156144 @default.
• W2809898434 cites W2325234563 @default.
• W2809898434 cites W2574527709 @default.
• W2809898434 cites W2585889897 @default.
• W2809898434 cites W2610772121 @default.
• W2809898434 cites W2621226858 @default.
• W2809898434 cites W4300830012 @default.
• W2809898434 doi "https://doi.org/10.1016/j.ophtha.2018.04.039" @default.
• W2809898434 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6566865" @default.
• W2809898434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29980333" @default.
• W2809898434 hasPublicationYear "2018" @default.
• W2809898434 type Work @default.
• W2809898434 sameAs 2809898434 @default.
• W2809898434 citedByCount "25" @default.
• W2809898434 countsByYear W28098984342020 @default.
• W2809898434 countsByYear W28098984342021 @default.
• W2809898434 countsByYear W28098984342022 @default.
• W2809898434 countsByYear W28098984342023 @default.
• W2809898434 crossrefType "journal-article" @default.
• W2809898434 hasAuthorship W2809898434A5015264417 @default.
• W2809898434 hasAuthorship W2809898434A5021501498 @default.
• W2809898434 hasAuthorship W2809898434A5023376839 @default.
• W2809898434 hasAuthorship W2809898434A5053593038 @default.
• W2809898434 hasAuthorship W2809898434A5057741978 @default.
• W2809898434 hasAuthorship W2809898434A5058951987 @default.
• W2809898434 hasAuthorship W2809898434A5059376308 @default.
• W2809898434 hasAuthorship W2809898434A5061503632 @default.
• W2809898434 hasBestOaLocation W28098984342 @default.
• W2809898434 hasConcept C118487528 @default.
• W2809898434 hasConcept C119767625 @default.
• W2809898434 hasConcept C126322002 @default.
• W2809898434 hasConcept C134018914 @default.
• W2809898434 hasConcept C141071460 @default.
• W2809898434 hasConcept C2776694085 @default.
• W2809898434 hasConcept C2777802072 @default.
• W2809898434 hasConcept C2778257484 @default.
• W2809898434 hasConcept C2779829184 @default.
• W2809898434 hasConcept C2781100027 @default.
• W2809898434 hasConcept C2908627140 @default.
• W2809898434 hasConcept C2985127711 @default.
• W2809898434 hasConcept C44249647 @default.
• W2809898434 hasConcept C555293320 @default.
• W2809898434 hasConcept C71924100 @default.
• W2809898434 hasConceptScore W2809898434C118487528 @default.
• W2809898434 hasConceptScore W2809898434C119767625 @default.
• W2809898434 hasConceptScore W2809898434C126322002 @default.
• W2809898434 hasConceptScore W2809898434C134018914 @default.
• W2809898434 hasConceptScore W2809898434C141071460 @default.
• W2809898434 hasConceptScore W2809898434C2776694085 @default.
• W2809898434 hasConceptScore W2809898434C2777802072 @default.
• W2809898434 hasConceptScore W2809898434C2778257484 @default.
• W2809898434 hasConceptScore W2809898434C2779829184 @default.
• W2809898434 hasConceptScore W2809898434C2781100027 @default.
• W2809898434 hasConceptScore W2809898434C2908627140 @default.
• W2809898434 hasConceptScore W2809898434C2985127711 @default.
• W2809898434 hasConceptScore W2809898434C44249647 @default.
• W2809898434 hasConceptScore W2809898434C555293320 @default.
• W2809898434 hasConceptScore W2809898434C71924100 @default.
• W2809898434 hasIssue "11" @default.
• W2809898434 hasLocation W28098984341 @default.
• W2809898434 hasLocation W28098984342 @default.
• W2809898434 hasLocation W28098984343 @default.
• W2809898434 hasLocation W28098984344 @default.
• W2809898434 hasOpenAccess W2809898434 @default.
• W2809898434 hasPrimaryLocation W28098984341 @default.
• W2809898434 hasRelatedWork W1988341374 @default.
• W2809898434 hasRelatedWork W2062091766 @default.
• W2809898434 hasRelatedWork W2769953754 @default.
• W2809898434 hasRelatedWork W2790038519 @default.
• W2809898434 hasRelatedWork W2809898434 @default.
• W2809898434 hasRelatedWork W2994033573 @default.
• W2809898434 hasRelatedWork W3096757714 @default.
• W2809898434 hasRelatedWork W4238986165 @default.
• W2809898434 hasRelatedWork W4362511091 @default.
• W2809898434 hasRelatedWork W748801892 @default.
• W2809898434 hasVolume "125" @default.
• W2809898434 isParatext "false" @default.
• W2809898434 isRetracted "false" @default.
• W2809898434 magId "2809898434" @default.
• W2809898434 workType "article" @default.